Compare Nuscale Power Corporation (SMR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Sanofi SA — how do they compare? Nuscale Power Corporation trades at $10.84 (market cap $4.59B), while Sanofi SA trades at $42.71 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 22.7× Nuscale Power Corporation's market cap, and Sanofi SA pays a 5.61% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| SMR | SNY | |
|---|---|---|
Market Cap | $4.59B | $104.06B |
Sector | Utilities | Health |
52-Week High | $53.43 | $52.34 |
52-Week Low | $7.59 | $41.33 |
Enterprise Value | $3.52B | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR stock surged 15.32% to $11.18, showing strong bullish momentum with technical indicators supporting the uptrend. The company maintains a substantial cash position of $1.9 billion despite significant operating losses and negative profit margins. Recent news highlights NuScale's positioning in the nuclear energy sector, particularly for AI power demands, though the company remains years away from commercial deployment.
The outlook remains speculative with Wall Street divided - 50% of analysts recommend Buy with a $11.25 consensus target. Key risks include cash burn acceleration, lack of firm commercial contracts, and execution challenges in bringing small modular reactors to market. The stock offers high-risk/high-reward potential for investors betting on nuclear energy adoption.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
